Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)-Reference-Cited by-同舟云学术

Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

Published:2019-03-20 Issue:6 Volume:20 Page:877-885
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Wu Jiaxin¹²,Wang Aoli¹,Li Xixiang¹³,Chen Cheng¹²,Qi Ziping¹³,Hu Chen¹²,Wang Wenliang¹²,Wu Hong¹,Huang Tao⁴,Zhao Ming⁴,Wang Wenchao¹³,Hu Zhenquan¹,Liu Qingwang⁴,Wang Beilei¹²,Wang Li¹²,Li Lili⁵,Ge Jian⁵,Ren Tao⁴,Xia Ruixiang⁵,Liu Jing¹³^ORCID,Liu Qingsong¹²³⁴^ORCID

Affiliation:

1. High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, Anhui, P. R. China

2. University of Science and Technology of China, Hefei, Anhui, P. R. China

3. CHMFL-HCMTC Target Therapy Joint Laboratory, Hefei, Anhui, P. R. China

4. Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, P. R. China

5. Department of Hematology, the First Hospital of Anhui Medical University, Hefei, Anhui, P.R. China

Funder

National Natural Science Foundation of China

The National Natural Science Foundation of China

the Postdoctoral Innovative Talents Support Program

The Natural Science Foundation of Anhui province

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2019.1579958